

UNITED STATES BANKRUPTCY COURT

DISTRICT OF Delaware

In re: Insys Therapeutics, Inc., et al.

§
§
§
§

Case No. 19-11292

Lead Case No. 19-11292

Debtor(s)

Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 03/31/2022

Petition Date: 06/10/2019

Plan Confirmed Date: 01/16/2020

Plan Effective Date: 02/18/2020

This Post-confirmation Report relates to: Reorganized Debtor

Other Authorized Party or Entity: Insys Liquidation Trust

Name of Authorized Party or Entity

/s/ Alan D. Halperin

Signature of Responsible Party

05/16/2022

Date

Alan D. Halperin

Printed Name of Responsible Party

Halperin Battaglia Benzija, LLP
40 Wall Street, 37th Floor
New York, NY 10005

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

Part 1: Summary of Post-confirmation Transfers

| | Current Quarter | Total Since Effective Date |
|--|-----------------|----------------------------|
| a. Total cash disbursements | \$553,809 | \$21,418,420 |
| b. Non-cash securities transferred | \$0 | \$0 |
| c. Other non-cash property transferred | \$0 | \$0 |
| d. Total transferred (a+b+c) | \$553,809 | \$21,418,420 |

Part 2: Preconfirmation Professional Fees and Expenses

| a. | | | Approved Current Quarter | Approved Cumulative | Paid Current Quarter | Paid Cumulative |
|-----------------------------------|---|------------------------|--------------------------|---------------------|----------------------|-----------------|
| | Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i> | | | \$0 | \$0 | \$0 |
| <i>Itemized Breakdown by Firm</i> | | | | | | |
| | Firm Name | Role | | | | |
| i | ALTO Litigation | Special Counsel | \$0 | \$0 | \$0 | \$2,838 |
| ii | Andersen Tax | Financial Professional | \$0 | \$0 | \$0 | \$60,664 |
| iii | Carlton Fields | Other | \$0 | \$0 | \$0 | \$435,811 |
| iv | Columbus | Other | \$0 | \$0 | \$0 | \$3,900 |
| v | Dinsmore & Shohi | Special Counsel | \$0 | \$0 | \$0 | \$4,538 |
| vi | DLA Piper | Special Counsel | \$0 | \$0 | \$0 | \$3,942 |
| vii | Ernst & Young | Financial Professional | \$0 | \$0 | \$0 | \$5,200 |
| viii | Epiq | Other | \$0 | \$0 | \$0 | \$1,124,069 |
| ix | FTI Consulting | Financial Professional | \$0 | \$0 | \$0 | \$3,891,025 |
| x | Gibbons | Special Counsel | \$0 | \$0 | \$0 | \$8,525 |
| xi | Hampton Barghois Pierce | Special Counsel | \$0 | \$0 | \$0 | \$3,483 |
| xii | Holland & Knight | Special Counsel | \$0 | \$0 | \$0 | \$120,436 |
| xiii | Lazard Freres | Financial Professional | \$0 | \$0 | \$0 | \$1,478,864 |
| xiv | Miller Friel | Special Counsel | \$0 | \$0 | \$0 | \$69,684 |
| xv | Rakoczy Molion Mazzochi | Special Counsel | \$0 | \$0 | \$0 | \$5,917 |
| xvi | Resolutions Inc. | Special Counsel | \$0 | \$0 | \$0 | \$25,000 |
| xvii | Richards Layton & Finger | Special Counsel | \$0 | \$0 | \$0 | \$1,018,507 |
| xviii | Rose Law Firm | Special Counsel | \$0 | \$0 | \$0 | \$3,617 |
| xix | Shook Hardy & Bacon | Special Counsel | \$0 | \$0 | \$0 | \$543 |
| xx | Spiro Harrison | Special Counsel | \$0 | \$0 | \$0 | \$45,839 |
| xxi | Squire Patton Boggs | Special Counsel | \$0 | \$0 | \$0 | \$354 |
| xxii | Weil Gotshal & Manges | Lead Counsel | \$0 | \$0 | \$0 | \$1,759,519 |
| xxiii | Wilson Sonsini Goodrich & Ro | Special Counsel | \$0 | \$0 | \$0 | \$127,690 |
| xxiv | | | | | | |
| xxv | | | | | | |
| xxvi | | | | | | |
| xxvii | | | | | | |
| xxviii | | | | | | |
| xxix | | | | | | |

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

| | | | | | | |
|---------|--|--|--|--|--|--|
| xxx | | | | | | |
| xxxii | | | | | | |
| xxxiii | | | | | | |
| xxxiv | | | | | | |
| xxxv | | | | | | |
| xxxvi | | | | | | |
| xxxvii | | | | | | |
| xxxviii | | | | | | |
| xxxix | | | | | | |
| xl | | | | | | |
| xli | | | | | | |
| xlii | | | | | | |
| xliii | | | | | | |
| xliv | | | | | | |
| xlv | | | | | | |
| xlvi | | | | | | |
| xlvii | | | | | | |
| xlviii | | | | | | |
| xlix | | | | | | |
| l | | | | | | |
| li | | | | | | |
| lii | | | | | | |
| liii | | | | | | |
| liv | | | | | | |
| lv | | | | | | |
| lvi | | | | | | |
| lvii | | | | | | |
| lviii | | | | | | |
| lix | | | | | | |
| lx | | | | | | |
| lxi | | | | | | |
| lxii | | | | | | |
| lxiii | | | | | | |
| lxiv | | | | | | |
| lxv | | | | | | |
| lxvi | | | | | | |
| lxvii | | | | | | |
| lxviii | | | | | | |
| lxix | | | | | | |
| lxx | | | | | | |
| lxxi | | | | | | |

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

| | | | | | |
|---------|--|--|--|--|--|
| lxxii | | | | | |
| lxxiii | | | | | |
| lxxiv | | | | | |
| lxxv | | | | | |
| lxxvi | | | | | |
| lxxvii | | | | | |
| lxxviii | | | | | |
| lxxix | | | | | |
| lxxx | | | | | |
| lxxxi | | | | | |
| lxxxii | | | | | |
| lxxxiii | | | | | |
| lxxxiv | | | | | |
| lxxxv | | | | | |
| lxxxvi | | | | | |
| lxxxvi | | | | | |
| lxxxvi | | | | | |
| lxxxix | | | | | |
| xc | | | | | |
| xc | | | | | |
| xcii | | | | | |
| xciii | | | | | |
| xciv | | | | | |
| xcv | | | | | |
| xcvi | | | | | |
| xcvii | | | | | |
| xcviii | | | | | |
| xcix | | | | | |
| c | | | | | |
| ci | | | | | |

| | | Approved Current Quarter | Approved Cumulative | Paid Current Quarter | Paid Cumulative | |
|----|---|--------------------------|---------------------|----------------------|-----------------|--|
| b. | Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor | <i>Aggregate Total</i> | | | | |
| | <i>Itemized Breakdown by Firm</i> | | | | | |
| | | Firm Name | Role | | | |
| | i | | | | | |
| | ii | | | | | |
| | iii | | | | | |
| | iv | | | | | |
| v | | | | | | |
| vi | | | | | | |

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

| | | | | | | |
|---------|--|--|--|--|--|--|
| vii | | | | | | |
| viii | | | | | | |
| ix | | | | | | |
| x | | | | | | |
| xi | | | | | | |
| xii | | | | | | |
| xiii | | | | | | |
| xiv | | | | | | |
| xv | | | | | | |
| xvi | | | | | | |
| xvii | | | | | | |
| xviii | | | | | | |
| xix | | | | | | |
| xx | | | | | | |
| xxi | | | | | | |
| xxii | | | | | | |
| xxiii | | | | | | |
| xxiv | | | | | | |
| xxv | | | | | | |
| xxvi | | | | | | |
| xxvii | | | | | | |
| xxviii | | | | | | |
| xxix | | | | | | |
| xxx | | | | | | |
| xxxi | | | | | | |
| xxxii | | | | | | |
| xxxiii | | | | | | |
| xxxiv | | | | | | |
| xxxv | | | | | | |
| xxxvi | | | | | | |
| xxxvii | | | | | | |
| xxxviii | | | | | | |
| xxxix | | | | | | |
| xl | | | | | | |
| xli | | | | | | |
| xlii | | | | | | |
| xliii | | | | | | |
| xliv | | | | | | |
| xlv | | | | | | |
| xlvi | | | | | | |
| xlvii | | | | | | |
| xlviii | | | | | | |

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

| | | | | | | |
|---------|--|--|--|--|--|--|
| xlix | | | | | | |
| l | | | | | | |
| li | | | | | | |
| lii | | | | | | |
| liii | | | | | | |
| liv | | | | | | |
| lv | | | | | | |
| lvi | | | | | | |
| lvii | | | | | | |
| lviii | | | | | | |
| lix | | | | | | |
| lx | | | | | | |
| lxi | | | | | | |
| lxii | | | | | | |
| lxiii | | | | | | |
| lxiv | | | | | | |
| lxv | | | | | | |
| lxvi | | | | | | |
| lxvii | | | | | | |
| lxviii | | | | | | |
| lxix | | | | | | |
| lxx | | | | | | |
| lxxi | | | | | | |
| lxxii | | | | | | |
| lxxiii | | | | | | |
| lxxiv | | | | | | |
| lxxv | | | | | | |
| lxxvi | | | | | | |
| lxxvii | | | | | | |
| lxxviii | | | | | | |
| lxxix | | | | | | |
| lxxx | | | | | | |
| lxxxii | | | | | | |
| lxxxiii | | | | | | |
| lxxxiv | | | | | | |
| lxxxv | | | | | | |
| lxxxvi | | | | | | |
| lxxxvi | | | | | | |
| lxxxvi | | | | | | |
| lxxxix | | | | | | |
| xc | | | | | | |

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

| | | | | | | |
|--------|--|--|--|--|--|--|
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |
| xcviii | | | | | | |
| xcvii | | | | | | |
| xcvi | | | | | | |
| xcv | | | | | | |
| xciv | | | | | | |
| xciii | | | | | | |
| xcii | | | | | | |

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ William H. Henrich

Signature of Responsible Party

Liquidating Trustee of the Insys Liquidation Trust

Title

William H. Henrich


Printed Name of Responsible Party

05/16/2022


Date

Debtor's Name Insys Therapeutics, Inc., et al.


Case No. 19-11292



Page 1



Other Page 1



Page 2 Minus Tables

Bankruptcy Table 1-50

Debtor's Name Insys Therapeutics, Inc., et al.

Case No. 19-11292




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INSYS THERAPEUTICS, INC., *et al.*,

Liquidating Debtors.¹

Chapter 11

Case No. 19-11292 (JTD)

(Jointly Administered)

Notes to Post-Confirmation Report

Quarter Ending Date: 03/31/2022

On June 10, 2019 (the “Petition Date”), the Debtors each commenced with this Court a voluntary case under chapter 11 of the Bankruptcy Code (the “Chapter 11 Cases”).

On January 16, 2020, this Court entered an order [Docket No. 1115] (the “Confirmation Order”) confirming the *Second Amended Joint Chapter 11 Plan of Liquidation of Insys Therapeutics, Inc. and Its Affiliated Debtors* (the “Plan”) in the Chapter 11 Cases. As provided for in the Confirmation Order, all assets and liabilities of the Debtors were substantively consolidated and substantive consolidation would be implemented for distribution purposes in accordance with the Plan. On February 18, 2020 (the “Effective Date”), the Plan became effective in accordance with its terms and, in accordance with the Plan, Confirmation Order and that certain *Trust Agreement for Insys Liquidation Trust* (the “Trust Agreement”), certain assets of the Debtors existing as of such date were transferred to and became vested in the Liquidation Trust, and William Henrich was appointed the liquidating trustee (the “Trustee”) of the Insys Liquidation Trust (the “Trust”).

The Trust is filing the quarterly post-confirmation report (the “PCR”) solely for the purposes of reporting to the Office of the United States Trustee for the District of Delaware. The following notes, statements, and limitations should be referred to and referenced in connection with any review of the PCR. Capitalized terms used but not otherwise defined herein have the meanings given to them in the Plan.

Note to Part 1a: Total cash disbursements since the Effective Date: In accordance with the BTcP Subsys Asset Purchase Agreement, which was approved by this Court on September 19, 2019 [Docket No. 641], accounts receivables totaling \$794,671.95 received from third parties were turned over to the buyer, BTcP, and therefore were not property of the estate. Accordingly, these amounts are not included as income or disbursements of the Trust.

Note to Part 2: Pre-confirmation Professional Fees and Expenses: Pre-confirmation professional fees paid by the Trust since the Effective Date are provided under the “Approved

¹ The Liquidating Debtors in these cases, along with the last four digits of each Debtor’s federal tax identification number, are: Insys Therapeutics, Inc. (7886); IC Operations, LLC (9659), Insys Development Company, Inc. (3020); Insys Manufacturing, LLC (0789); Insys Pharma, Inc. (9410); IPSC, LLC (6577); and IPT 355, LLC (0155).

Cumulative” column. Upon information and belief, all fees have been satisfied in full. The Trust is not able to report all professional fees approved and paid since the Petition Date.

Note to part 3: Recoveries of the Holders of Claims and Interests Under Confirmed Plan: Reconciliation of all claims, including administrative, secured and priority claims remain ongoing. All such claims that have been allowed have been paid in full. The Trust is also reviewing and reconciling all general unsecured claims and have not been any distributions to date. Lastly, equity interests were deemed cancelled under the Plan and as such, no distribution will be made on account of such interests.

Reservation of Rights: Given the complexity of the Debtors’ books and records and the ongoing administration of the Trust, inadvertent errors or omissions may have occurred. The Trustee reserves all rights to amend or supplement the PCR in all respects as may be necessary or appropriate. Nothing contained in this PCR shall constitute an admission of any kind or nature or a waiver of any rights of the Trust or the Trustee, all of which are expressly reserved in full.

The Post-confirmation Report was executed by William H. Henrich solely in his capacity as Trustee of the Insys Liquidation Trust.